{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:19Z","timestamp":1772119399450,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060810"],"award-info":[{"award-number":["82060810"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2020LCZXKF-XY05"],"award-info":[{"award-number":["2020LCZXKF-XY05"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2020LCZXKF-XY08"],"award-info":[{"award-number":["2020LCZXKF-XY08"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2021LCZXXF-XY09"],"award-info":[{"award-number":["2021LCZXXF-XY09"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2022LCZXKF-XY01"],"award-info":[{"award-number":["2022LCZXKF-XY01"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2020LCZXKF-XY05"],"award-info":[{"award-number":["2020LCZXKF-XY05"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2020LCZXKF-XY08"],"award-info":[{"award-number":["2020LCZXKF-XY08"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2021LCZXXF-XY09"],"award-info":[{"award-number":["2021LCZXXF-XY09"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2022LCZXKF-XY01"],"award-info":[{"award-number":["2022LCZXKF-XY01"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2020LCZXKF-XY05"],"award-info":[{"award-number":["2020LCZXKF-XY05"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2020LCZXKF-XY08"],"award-info":[{"award-number":["2020LCZXKF-XY08"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2021LCZXXF-XY09"],"award-info":[{"award-number":["2021LCZXXF-XY09"]}]},{"name":"Open Project of Yunnan Blood Clinical Medical Center","award":["2022LCZXKF-XY01"],"award-info":[{"award-number":["2022LCZXKF-XY01"]}]},{"name":"Yunnan Provincial Department of Science and Technology\u2014Kunming Medical University Joint Special Project on Applied Basic Research","award":["202101AY070001-027"],"award-info":[{"award-number":["202101AY070001-027"]}]},{"name":"Yunnan Provincial Department of Science and Technology\u2014Kunming Medical University Joint Special Project on Applied Basic Research","award":["202201AY070001-230"],"award-info":[{"award-number":["202201AY070001-230"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01242-7","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T14:01:42Z","timestamp":1699106502000},"page":"4623-4632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytokine levels in patients with non-M3 myeloid leukemia are key indicators of how well the disease responds to chemotherapy"],"prefix":"10.1007","volume":"23","author":[{"given":"Rui","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosui","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezhong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengzheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyun","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"issue":"9","key":"1242_CR1","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481\u20135.","journal-title":"Blood"},{"issue":"1","key":"1242_CR2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hon.2900070106","volume":"7","author":"JA Copplestone","year":"1989","unstructured":"Copplestone JA, Smith AG, Osmond C, et al. Treatment of acute myeloid leukemia in the elderly: a clinical dilemma. Hematol Oncol. 1989;7(1):53\u20139.","journal-title":"Hematol Oncol"},{"issue":"12","key":"1242_CR3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"1242_CR4","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.clml.2015.02.031","volume":"15","author":"EJ Feldman","year":"2015","unstructured":"Feldman EJ. Novel therapeutics for therapy-related acute myeloid leukemia: 2014. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S91-93.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1242_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2018.10.017","volume":"75","author":"L Jakovic","year":"2018","unstructured":"Jakovic L, Bogdanovic A, Djordjevic V, et al. The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities. Leuk Res. 2018;75:23\u20138.","journal-title":"Leuk Res"},{"issue":"13","key":"1242_CR6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189\u201399.","journal-title":"N Engl J Med"},{"issue":"12","key":"1242_CR7","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jamaoncol.2020.4599","volume":"6","author":"D Jeyakumar","year":"2020","unstructured":"Jeyakumar D, O\u2019brien S. Minimal residual disease in acute myeloid leukemia. JAMA Oncol. 2020;6(12):1899\u2013900.","journal-title":"JAMA Oncol"},{"key":"1242_CR8","doi-asserted-by":"crossref","first-page":"155508","DOI":"10.1016\/j.cyto.2021.155508","volume":"142","author":"O Karimdadi Sariani","year":"2021","unstructured":"Karimdadi Sariani O, Eghbalpour S, Kazemi E, et al. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. Cytokine. 2021;142:155508.","journal-title":"Cytokine"},{"issue":"13","key":"1242_CR9","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DKT, Eide CA, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204\u201318.","journal-title":"Cell Rep"},{"issue":"2","key":"1242_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI114186","volume":"84","author":"W Oster","year":"1989","unstructured":"Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Investig. 1989;84(2):451\u20137.","journal-title":"J Clin Investig"},{"issue":"6","key":"1242_CR11","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.V71.6.1759.1759","volume":"71","author":"AG Leary","year":"1988","unstructured":"Leary AG, Ikebuchi K, Hirai Y, et al. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha. Blood. 1988;71(6):1759\u201363.","journal-title":"Blood"},{"key":"1242_CR12","doi-asserted-by":"crossref","first-page":"106180","DOI":"10.1016\/j.leukres.2019.106180","volume":"84","author":"V Vijay","year":"2019","unstructured":"Vijay V, Miller R, Vue GS, et al. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leuk Res. 2019;84:106180.","journal-title":"Leuk Res"},{"issue":"1\u20132","key":"1242_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-1759(01)00407-0","volume":"254","author":"EB Cook","year":"2001","unstructured":"Cook EB, Stahl JL, Lowe L, et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods. 2001;254(1\u20132):109\u201318.","journal-title":"J Immunol Methods"},{"issue":"12","key":"1242_CR14","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.21493","volume":"104","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer. 2005;104(12):2726\u201334.","journal-title":"Cancer"},{"issue":"2","key":"1242_CR15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12185-022-03328-6","volume":"116","author":"A Marumo","year":"2022","unstructured":"Marumo A, Wakita S, Morita K, et al. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. Int J Hematol. 2022;116(2):199\u2013214.","journal-title":"Int J Hematol"},{"issue":"20","key":"1242_CR16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"20","key":"1242_CR17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","volume":"135","author":"RP Hasserjian","year":"2020","unstructured":"Hasserjian RP, Steensma DP, Graubert TA, et al. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood. 2020;135(20):1729\u201338.","journal-title":"Blood"},{"issue":"3","key":"1242_CR18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jped.2015.08.008","volume":"92","author":"MC De Lima","year":"2016","unstructured":"De Lima MC, Da Silva DB, Freund AP, et al. Acute Myeloid Leukemia: analysis of epidemiological profile and survival rate. J Pediatr. 2016;92(3):283\u20139.","journal-title":"J Pediatr"},{"issue":"2","key":"1242_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humimm.2013.11.014","volume":"75","author":"YX Sun","year":"2014","unstructured":"Sun YX, Kong HL, Liu CF, et al. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol. 2014;75(2):113\u20138.","journal-title":"Hum Immunol"},{"issue":"1","key":"1242_CR20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12885-020-07222-4","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang H, Wang W, et al. Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients. BMC Cancer. 2020;20(1):732.","journal-title":"BMC Cancer"},{"issue":"1","key":"1242_CR21","first-page":"1184","volume":"27","author":"Y Sun","year":"2022","unstructured":"Sun Y, Zhang F, Huo L, et al. Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations. Hematology (Amsterdam, Netherlands). 2022;27(1):1184\u201390.","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"6","key":"1242_CR22","first-page":"1757","volume":"29","author":"JL Ma","year":"2021","unstructured":"Ma JL, Zhou AQ, Gu SY, et al. Clinical and cytogenetical characteristics in acute myeloid leukemia with myelodysplasia-related changes. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(6):1757\u201362.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"1242_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125\u201339.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1242_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4274\/tjh.2012.0164","volume":"31","author":"Z Sepehrizadeh","year":"2014","unstructured":"Sepehrizadeh Z, Mohammadi M, Emami A, et al. Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy. Turk J Haematol. 2014;31(2):149\u201354.","journal-title":"Turk J Haematol"},{"issue":"1","key":"1242_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","volume":"74","author":"T Kishimoto","year":"1989","unstructured":"Kishimoto T. The biology of interleukin-6. Blood. 1989;74(1):1\u201310.","journal-title":"Blood"},{"issue":"7","key":"1242_CR26","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40(7):1830\u20135.","journal-title":"Eur J Immunol"},{"key":"1242_CR27","doi-asserted-by":"crossref","first-page":"748585","DOI":"10.3389\/fimmu.2021.748585","volume":"12","author":"Z Li","year":"2021","unstructured":"Li Z, Yang Z, Hu P, et al. cytokine expression of lung bacterial infection in newly diagnosed adult hematological malignancies. Front Immunol. 2021;12:748585.","journal-title":"Front Immunol"},{"key":"1242_CR28","doi-asserted-by":"crossref","first-page":"860526","DOI":"10.3389\/fcimb.2022.860526","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang J, He H, et al. Increased cytokine levels assist in the diagnosis of respiratory bacterial infections or concurrent bacteremia in patients with non-Hodgkin\u2019s lymphoma. Front Cell Infect Microbiol. 2022;12:860526.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"1242_CR29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","volume":"14","author":"WE Naugler","year":"2008","unstructured":"Naugler WE, Karin M. The wolf in sheep\u2019s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109\u201319.","journal-title":"Trends Mol Med"},{"issue":"9","key":"1242_CR30","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2010.31.8907","volume":"30","author":"P Sansone","year":"2012","unstructured":"Sansone P, Bromberg J. Targeting the interleukin-6\/Jak\/stat pathway in human malignancies. J Clin Oncol. 2012;30(9):1005\u201314.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1242_CR31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2010.02.026","volume":"46","author":"T Ara","year":"2010","unstructured":"Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (Oxford, England: 1990). 2010;46(7):1223\u201331.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"6","key":"1242_CR32","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V74.6.2081.2081","volume":"74","author":"CE Van Der Schoot","year":"1989","unstructured":"Van Der Schoot CE, Jansen P, Poorter M, et al. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood. 1989;74(6):2081\u20137.","journal-title":"Blood"},{"issue":"1","key":"1242_CR33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000203547","volume":"98","author":"P Koistinen","year":"1997","unstructured":"Koistinen P, S\u00e4ily M, Poromaa N, et al. Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol. 1997;98(1):14\u201321.","journal-title":"Acta Haematol"},{"issue":"2","key":"1242_CR34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04011.x","volume":"158","author":"C Wu","year":"2009","unstructured":"Wu C, Wang S, Wang F, et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 2009;158(2):199\u2013204.","journal-title":"Clin Exp Immunol"},{"issue":"21","key":"1242_CR35","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","volume":"14","author":"DJ Waugh","year":"2008","unstructured":"Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735\u201341.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1242_CR36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1684\/ecn.2012.0322","volume":"23","author":"H Reikvam","year":"2012","unstructured":"Reikvam H, Hatfield KJ, Fredly H, et al. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw. 2012;23(4):140\u201353.","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"1242_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1034\/j.1600-0609.2003.00080.x","volume":"71","author":"\u00d8 Bruserud","year":"2003","unstructured":"Bruserud \u00d8, Glenjen N, Ryningen A. Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts. Eur J Haematol. 2003;71(1):9\u201317.","journal-title":"Eur J Haematol"},{"issue":"6","key":"1242_CR38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/mpo.1244","volume":"37","author":"ES De Bont","year":"2001","unstructured":"De Bont ES, Vellenga E, Molema G, et al. A possible role for spontaneous interleukin-8 production by acute myeloid leukemic cells in angiogenesis related processes: work in progress. Med Pediatr Oncol. 2001;37(6):511\u20137.","journal-title":"Med Pediatr Oncol"},{"issue":"12","key":"1242_CR39","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1177\/0300060518800588","volume":"46","author":"L Feng","year":"2018","unstructured":"Feng L, Qi Q, Wang P, et al. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res. 2018;46(12):5228\u201336.","journal-title":"J Int Med Res"},{"issue":"7","key":"1242_CR40","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/08820139.2017.1360342","volume":"46","author":"MMM Sanguinete","year":"2017","unstructured":"Sanguinete MMM, Oliveira PH, Martins-Filho A, et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest. 2017;46(7):677\u201388.","journal-title":"Immunol Invest"},{"issue":"22","key":"1242_CR41","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","volume":"20","author":"MF Sanmamed","year":"2014","unstructured":"Sanmamed MF, Carranza-Rua O, Alfaro C, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res. 2014;20(22):5697\u2013707.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1242_CR42","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/sj.bjc.6602227","volume":"91","author":"YM Zhu","year":"2004","unstructured":"Zhu YM, Webster SJ, Flower D, et al. Interleukin-8\/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 2004;91(11):1970\u20136.","journal-title":"Br J Cancer"},{"key":"1242_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.04.002","volume":"454","author":"J Zhai","year":"2019","unstructured":"Zhai J, Shen J, Xie G, et al. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. Cancer Lett. 2019;454:37\u201343.","journal-title":"Cancer Lett"},{"key":"1242_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2018.09.032","volume":"840","author":"M Cheng","year":"2018","unstructured":"Cheng M, Cai W, Huang W, et al. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription. Eur J Pharmacol. 2018;840:1\u20138.","journal-title":"Eur J Pharmacol"},{"key":"1242_CR45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","volume":"29","author":"W Ouyang","year":"2011","unstructured":"Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71\u2013109.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1242_CR46","doi-asserted-by":"crossref","first-page":"e20190418","DOI":"10.1084\/jem.20190418","volume":"217","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Vieira P, O\u2019garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217(1):e20190418.","journal-title":"J Exp Med"},{"issue":"4","key":"1242_CR47","first-page":"2388","volume":"13","author":"Z Li","year":"2021","unstructured":"Li Z, Liu J, Man Y, et al. Analysis of cytokine risk factors in the early death of patients with secondary phagocytic lymphocytic histiocytosis. Am J Transl Res. 2021;13(4):2388\u201398.","journal-title":"Am J Transl Res"},{"issue":"20","key":"1242_CR48","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2010-01-262071","volume":"116","author":"SM Kornblau","year":"2010","unstructured":"Kornblau SM, Mccue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010;116(20):4251\u201361.","journal-title":"Blood"},{"issue":"1","key":"1242_CR49","first-page":"7","volume":"36","author":"HH Park","year":"2006","unstructured":"Park HH, Kim M, Lee BH, et al. Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci. 2006;36(1):7\u201315.","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"1242_CR50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.23785","volume":"113","author":"AM Tsimberidou","year":"2008","unstructured":"Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008;113(7):1605\u201313.","journal-title":"Cancer"},{"issue":"3","key":"1242_CR51","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","volume":"61","author":"B Sanchez-Correa","year":"2013","unstructured":"Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61(3):885\u201391.","journal-title":"Cytokine"},{"issue":"9","key":"1242_CR52","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3109\/10428194.2012.666662","volume":"53","author":"JY Yoon","year":"2012","unstructured":"Yoon JY, Lafarge S, Dawe D, et al. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(9):1735\u201342.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1242_CR53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/1097-0142(20000801)89:3<551::AID-CNCR10>3.0.CO;2-E","volume":"89","author":"K Watari","year":"2000","unstructured":"Watari K, Tojo A, Nagamura-Inoue T, et al. Hyperfunction of neutrophils in a patient with BCR\/ABL negative chronic myeloid leukemia: a case report with in vitro studies. Cancer. 2000;89(3):551\u201360.","journal-title":"Cancer"},{"issue":"3","key":"1242_CR54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2141.2003.04118.x","volume":"120","author":"WG Wierda","year":"2003","unstructured":"Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol. 2003;120(3):452\u20136.","journal-title":"Br J Haematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01242-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T11:28:04Z","timestamp":1702726084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01242-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1242"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01242-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2541753\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,4]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The \"Helsinki Declaration\" and the \"International Code of Ethics for Biomedical Research Involving Humans,\" developed jointly by the Council of International Medical Science Organizations and\u00a0WHO\u00a0as well as the related standards of the Ethics Committee of Yunnan Province's First People's Hospital, were strictly obeyed throughout this study (Number: KHLL2022-KY075).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Patient consent was waived by the Ethics Committee of Yunnan Province's First People's Hospital due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}